Hypertension and dyslipidemia are major cardiovascular risk factors in people with diabetes, contributing significantly to morbidity and mortality. Optimal and early control of these comorbidities, especially in patients with coexisting chronic kidney disease (CKD), is crucial to reduce atherosclerotic cardiovascular disease (ASCVD) events. This case-based study aimed to evaluate comprehensive management strategies for blood pressure and lipid disorders in type 2 diabetes according to ADA 2025 and ESC/ESH 2024 recommendations.

A 63-year-old male with a 5-year history of type 2 diabetes, hypertension, and dyslipidemia, and recently diagnosed CKD was assessed for cardiovascular risk, treatment goals, and optimization strategy. Clinical evaluation, laboratory tests (HbA1c, lipid profile, eGFR, ACR), and imaging studies (echocardiography, carotid Doppler) were performed. Pharmacological therapy was adjusted according to individualized targets: BP <130/80 mmHg, HbA1c <7%, and LDL-C <1.4 mmol/L (55 mg/dL).

The patient’s initial BP was 150/80 mmHg, HbA1c 7.9%, and LDL-C 4.1 mmol/L. Treatment was optimized with fixed-dose combination therapy (Amlodipine/Valsartan, Vildagliptin/Metformin), high-intensity statin (Atorvastatin 40 mg), SGLT2 inhibitor (Dapagliflozin 10 mg), and low-dose aspirin. Follow-up demonstrated improved control of BP, lipids, and glycemia with good tolerance. The approach emphasized early combination therapy, guideline-directed drug classes with proven cardiorenal benefit, and patient education for lifestyle modification.

A multi-faceted approach integrating hypertension and lipid management in diabetes improves cardiovascular and renal outcomes. Personalized goals, fixed-dose combination therapy, and early use of SGLT2 inhibitors or RAAS blockers enhance treatment efficacy, adherence, and cost-effectiveness.